Related Experiment Video
Updated: Mar 5, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
New developments in the management of Waldenström macroglobulinemia
Jithma P Abeykoon1, Uday Yanamandra2, Prashant Kapoor3
1Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract:
Waldenström macroglobulinemia (WM) is a rare, immunoglobulin M -associated lymphoplasmacytic lymphoma. With the recent discoveries of CXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) and MYD88 mutations, our understanding of the biology of WM has expanded substantially. While WM still remains incurable, the field is rapidly evolving, and a number of promising agents with significant activity in this malignancy are being evaluated currently. In this review, we discuss the new developments that have occurred in WM over the past 15 years, with a focus on the role of ibrutinib, an oral Bruton's tyrosine kinase inhibitor that has recently been approved for WM in the United States, Europe, and Canada.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Nephrotic Syndrome III : Nursing Management
Mitral Stenosis III: Medical Management
Myocarditis III: Medical Management
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Nephrotic Syndrome II : Assessment and Medical Management

